Burstein HJ - Search Results

1

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Burstein HJ, et al. J Clin Oncol. 2001 May 15;19(10):2722-30. doi: 10.1200/JCO.2001.19.10.2722. J Clin Oncol. 2001. PMID: 11352965 Clinical Trial.

2

New cytotoxic agents and schedules for advanced breast cancer.

Burstein HJ, Bunnell CA, Winer EP. Burstein HJ, et al. Semin Oncol. 2001 Aug;28(4):344-58. doi: 10.1016/s0093-7754(01)90129-0. Semin Oncol. 2001. PMID: 11498829 Review.

3

New combinations with Herceptin in metastatic breast cancer.

Winer EP, Burstein HJ. Winer EP, et al. Among authors: burstein hj. Oncology. 2001;61 Suppl 2:50-7. doi: 10.1159/000055402. Oncology. 2001. PMID: 11694788 Review.

4

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.

Partridge AH, Burstein HJ, Winer EP. Partridge AH, et al. Among authors: burstein hj. J Natl Cancer Inst Monogr. 2001;(30):135-42. doi: 10.1093/oxfordjournals.jncimonographs.a003451. J Natl Cancer Inst Monogr. 2001. PMID: 11773307 Review.

5

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Burstein HJ, et al. Ann Oncol. 2005 Nov;16(11):1772-7. doi: 10.1093/annonc/mdi371. Epub 2005 Sep 8. Ann Oncol. 2005. PMID: 16150805 Free article. Clinical Trial.

6

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.

Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Mayer EL, et al. Among authors: burstein hj. Breast Cancer Res Treat. 2009 Oct;117(3):615-23. doi: 10.1007/s10549-009-0366-5. Epub 2009 Mar 18. Breast Cancer Res Treat. 2009. PMID: 19294501 Free PMC article. Clinical Trial.

7

Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.

Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJ. Olson EM, et al. Among authors: burstein hj. Ann Oncol. 2012 Jan;23(1):93-97. doi: 10.1093/annonc/mdr061. Epub 2011 Apr 29. Ann Oncol. 2012. PMID: 21531783 Free PMC article.

8

A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.

Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. Lin NU, et al. Among authors: burstein hj. Breast Cancer Res Treat. 2013 Jun;139(2):403-10. doi: 10.1007/s10549-013-2551-9. Epub 2013 May 5. Breast Cancer Res Treat. 2013. PMID: 23645007 Clinical Trial.

9

Phase I study of Doxil and vinorelbine in metastatic breast cancer.

Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Burstein HJ, et al. Ann Oncol. 1999 Sep;10(9):1113-6. doi: 10.1023/a:1008323200102. Ann Oncol. 1999. PMID: 10572612 Free article. Clinical Trial.

10

Docetaxel administered on a weekly basis for metastatic breast cancer.

Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Burstein HJ, et al. J Clin Oncol. 2000 Mar;18(6):1212-9. doi: 10.1200/JCO.2000.18.6.1212. J Clin Oncol. 2000. PMID: 10715290 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters